Retatrutide mimics GLP-1, GIP, and glucagon hormones to cut body weight by a quarter while improving blood sugar and inflammation, according to a global trial. Funded by Eli Lilly, the unapproved drug's findings were published in the Lancet and presented at the European Association for the Study of